PulseAugur
EN
LIVE 11:11:50
ENTITY Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry

Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry

PulseAugur coverage of Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry — every cluster mentioning Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry across labs, papers, and developer communities, ranked by signal.

Show in brief
Total · 30d
1
1 over 90d
Releases · 30d
0
0 over 90d
Papers · 30d
0
0 over 90d
TIER MIX · 90D
TOPICS
SENTIMENT · 30D

1 day(s) with sentiment data

RECENT · PAGE 1/1 · 1 TOTAL
  1. TOOL · CL_368617 ·

    Isomorphic Labs and MSD partner for AI-driven cancer drug discovery

    Isomorphic Labs and MSD have formed a partnership focused on utilizing AI for cancer drug discovery. Their collaboration aims to develop novel oncology drug therapies targeting small molecules.